JP2013507352A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507352A5
JP2013507352A5 JP2012532683A JP2012532683A JP2013507352A5 JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5 JP 2012532683 A JP2012532683 A JP 2012532683A JP 2012532683 A JP2012532683 A JP 2012532683A JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
composition according
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012532683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/002852 external-priority patent/WO2011042812A1/en
Publication of JP2013507352A publication Critical patent/JP2013507352A/ja
Publication of JP2013507352A5 publication Critical patent/JP2013507352A5/ja
Pending legal-status Critical Current

Links

JP2012532683A 2009-10-09 2010-10-08 進行性核上性麻痺の治療のためのラサギリンの使用 Pending JP2013507352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27867709P 2009-10-09 2009-10-09
US61/278,677 2009-10-09
PCT/IB2010/002852 WO2011042812A1 (en) 2009-10-09 2010-10-08 Use of rasagiline for the treatment of progressive supranuclear palsy

Publications (2)

Publication Number Publication Date
JP2013507352A JP2013507352A (ja) 2013-03-04
JP2013507352A5 true JP2013507352A5 (enExample) 2013-11-28

Family

ID=43533485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012532683A Pending JP2013507352A (ja) 2009-10-09 2010-10-08 進行性核上性麻痺の治療のためのラサギリンの使用

Country Status (7)

Country Link
US (1) US20110130466A1 (enExample)
EP (1) EP2485722A1 (enExample)
JP (1) JP2013507352A (enExample)
AU (1) AU2010304755A1 (enExample)
CA (1) CA2777185A1 (enExample)
IL (1) IL218948A0 (enExample)
WO (1) WO2011042812A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
WO2007117431A2 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
EA201170018A1 (ru) * 2008-06-13 2011-08-30 Тева Фармасьютикал Индастриз, Лтд. Разагилин для изменения течения болезни паркинсона
CN102065853A (zh) * 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
CA2767592A1 (en) 2009-07-09 2011-01-13 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
EP2004204B1 (en) * 2006-03-29 2012-09-12 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases with selenate
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
CN102065853A (zh) * 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
RU2013108256A (ru) * 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
AU2011282720B2 (en) * 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
MX2013004598A (es) * 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
HK1200315A1 (en) * 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
AU2012323351A1 (en) * 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan

Similar Documents

Publication Publication Date Title
JP2013507352A5 (enExample)
JP2013533287A5 (enExample)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2005506370A5 (enExample)
JP2016163571A5 (enExample)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JP2011516417A5 (enExample)
JP2013541583A5 (enExample)
JP2014521735A5 (enExample)
RU2013108258A (ru) Применение разагилина для лечения обонятельной дисфункции
JP2015155440A5 (enExample)
JP2011528333A5 (enExample)
JP2013509411A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2012517478A5 (enExample)
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
JP2014508758A5 (enExample)
JP2021073257A5 (enExample)
JP2012531402A5 (enExample)
JP2014524478A5 (enExample)
JP2008534503A5 (enExample)
JP2010500284A5 (enExample)
JP2011500589A5 (enExample)